Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
3 min read
Context Therapeutics has revealed preclinical studies, illustrating the distinct and potent effect of its Claudin 6-focused bispecific antibody CTIM-76
7 November 2023
Context Therapeutics has revealed promising preclinical results for its research asset, CTIM-76.
Drug Insights
5 min read
Glycyrrhetinic Acid Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
7 November 2023
This article summarized the latest R&D progress of Glycyrrhetinic Acid, the mechanism of action for Glycyrrhetinic Acid, and the drug target R&D trends for Glycyrrhetinic Acid.
Latest Hotspot
4 min read
Chimeric Therapeutics reports FDA's approval of IND application for CHM 2101, a new CDH17 CAR T cell treatment targeting advanced GI cancer
7 November 2023
Chimeric Therapeutics has disclosed that the US FDA has given the green light to the IND submission for CHM 2101.
Bio Sequence
3 min read
The Evolving Competitive Landscape Behind Vyjuvek, the World’s First-ever Topical Gene Therapy
7 November 2023
According to the Patsnap Bio Sequence Database, the top 10 applicants for the Vyjuvek patent are Krystal Biotech with 32 applications, Holostem Terapie Avanzate Srl with 6 applications, and FONDATION A DE ROTHSCHILD with 2 applications.
Latest Hotspot
3 min read
AceLink has unveiled the initial dosing of a patient in the Phase 2 clinical investigation of AL01211 for the treatment of Fabry Disease
6 November 2023
AceLink Therapeutics announced the initiation of AL01211 dosage for the first patient in its Phase 2 study for Fabry disease in China.
Drug Insights
4 min read
Halcinonide Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
6 November 2023
This article summarized the latest R&D progress of Halcinonide, the Mechanism of Action for Halcinonide, and the drug target R&D trends for Halcinonide.
Latest Hotspot
3 min read
At the annual SITC meeting, Nimbus Therapeutics unveiled encouraging initial results from a clinical study on an HPK1 inhibitor for solid tumors
6 November 2023
Nimbus Therapeutics, LLC has now shared preliminary findings from its ongoing Phase 1/2 trial of NDI-101150, an HPK1 small-molecule inhibitor.
Valuable Targets
6 min read
Analysis on the Clinical Research Progress of Factor Xa Inhibitor
6 November 2023
Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.
Latest Hotspot
3 min read
At SITC 2023, INmune Bio Inc. shared preclinical findings indicating INB03 as an innate immune checkpoint suppressor that reduces SIRPα
6 November 2023
Immunology firm, INmune Bio, Inc. will present its findings on the use of INB03 in managing high-risk MUC4 expressing HER2+ breast cancer. INB03 is a dominant-negative suppressor of soluble TNF.
Drug Insights
4 min read
A Comprehensive Review of Hydrocortisone Sodium Succinate's R&D Innovations and Drug Target Mechanism
6 November 2023
This article summarized the latest R&D progress of Hydrocortisone Sodium Succinate, the Mechanism of Action for Hydrocortisone Sodium Succinate, and the drug target R&D trends for Hydrocortisone Sodium Succinate.
Latest Hotspot
4 min read
Sarepta Therapeutics Releases Preliminary Findings of EMBARK, a Critical Global Trial on ELEVIDYS, a Gene Treatment for Duchenne Muscular Dystrophy
6 November 2023
Sarepta Therapeutics, Inc. shared initial results from EMBARK, a global Phase 3 trial evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in Duchenne muscular dystrophy patients aged 4-7.
Drug Insights
4 min read
Pharmaceutical Insights: Ibudilast's R&D Progress and its Mechanism of Action on Drug Target
6 November 2023
This article summarized the latest R&D progress of Ibudilast, the Mechanism of Action for Ibudilast, and the drug target R&D trends for Ibudilast.